Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States

J Med Econ. 2017 Nov;20(11):1123-1125. doi: 10.1080/13696998.2017.1360313. Epub 2017 Aug 11.

Authors

Catherine Saint-Laurent Thibault¹, Divya Moorjaney², Michael L Ganz³, Bruce Sill⁴, Shalini Hede⁵, Yong Yuan⁵, Boris Gorsh⁶

Affiliations

¹ a Evidera , Montreal , QC , Canada.
² b QuickPivot , Boston , MA , USA.
³ c Evidera , Waltham , MA , USA.
⁴ d Bristol-Myers Squibb , Hartford , CT , USA.
⁵ e Bristol-Myers Squibb , Plainsboro , NJ , USA.
⁶ f GlaxoSmithKline , Upper Providence , PA , USA.

PMID: 28745536
DOI: 10.1080/13696998.2017.1360313

No abstract available

MeSH terms

Carbamates
Cost-Benefit Analysis
Genotype
Hepatitis C, Chronic*
Humans
Imidazoles
Pyrrolidines
Sofosbuvir*
United States
Valine / analogs & derivatives

Substances

Carbamates
Imidazoles
Pyrrolidines
Valine
daclatasvir
Sofosbuvir